Faults are a concern for Multi-Agent Systems (MAS) designers, especially if the MAS are built for industrial or military use because there must be some guarantee of dependability. Some fault classification exists for classical systems, and is used to define faults. When dependability is at stake, such fault classification may be used from the beginning of the system’s conception to define fault classes and specify which types of faults are expected. Thus, one may want to use fault classification for MAS; however, From Fault Classification to Fault Tolerance for Multi-Agent Systems argues that working with autonomous and proactive agents implies a special analysis of the faults potentially occurring in the system. Moreover, the field of Fault Tolerance (FT) provides numerous methods adapted to handle different kinds of faults. Some handling methods have been studied within the MAS domain, adapting to their specificities and capabilities but increasing the large amount of FT methods. Therefore, unless being an expert in fault tolerance, it is difficult to choose, evaluate or compare fault tolerance methods, preventing a lot of developed applications from not only to being more pleasant to use but, more importantly, from at least being tolerant to common faults. From Fault Classification to Fault Tolerance for Multi-Agent Systems shows that specification phase guidelines and fault handler studies can be derived from the fault classification extension made for MAS. From this perspective, fault classification can become a unifying concept between fault tolerance methods in MAS.
Faults are a concern for Multi-Agent Systems (MAS) designers, especially if the MAS are built for industrial or military use because there must be some guarantee of dependability. Some fault classification exists for classical systems, and is used to define faults. When dependability is at stake, such fault classification may be used from the beginning of the system’s conception to define fault classes and specify which types of faults are expected. Thus, one may want to use fault classification for MAS; however, From Fault Classification to Fault Tolerance for Multi-Agent Systems argues that working with autonomous and proactive agents implies a special analysis of the faults potentially occurring in the system. Moreover, the field of Fault Tolerance (FT) provides numerous methods adapted to handle different kinds of faults. Some handling methods have been studied within the MAS domain, adapting to their specificities and capabilities but increasing the large amount of FT methods. Therefore, unless being an expert in fault tolerance, it is difficult to choose, evaluate or compare fault tolerance methods, preventing a lot of developed applications from not only to being more pleasant to use but, more importantly, from at least being tolerant to common faults. From Fault Classification to Fault Tolerance for Multi-Agent Systems shows that specification phase guidelines and fault handler studies can be derived from the fault classification extension made for MAS. From this perspective, fault classification can become a unifying concept between fault tolerance methods in MAS.
Drawing on the same standards of accuracy as the acclaimed DK Eyewitness Travel Guides, DK Top 10 Montreal & Quebec City uses exciting colorful photography and excellent cartography to provide a reliable and useful travel. Dozens of Top 10 lists provide vital information on each destination, as well as insider tips, from avoiding the crowds to finding out the freebies, The DK Top 10 Guides take the work out of planning any trip.
Neurologic side effects of cancer therapy can inhibit treatment, can be dose-limiting and can diminish quality-of-life. Neurotoxicity related to cancer therapy is a common problem in oncology practice and in clinical neurology. Recognition of neurologic complications of anticancer therapy is necessary due to potential confusion with metastatic disease, paraneoplastic syndromes or comorbid neurologic disorders that do not require reduction or discontinuation of therapy. Neurologic Complications of Cancer Therapy provides comprehensive coverage of the recognition and management of neurologic symptoms related to cancer therapy. The book includes sections on systemic therapy discussed by both agent and adverse event. The section on adverse events is particularly valuable to clinicians, allowing them to consult by symptom in cases where multiple agents have been administered and the source of the complication is uncertain. The systemic therapy section includes coverage of immunologic agents, biologics, and targeted therapies. The book also features sections on the complications of radiation therapy, complications of surgery and high-dose chemotherapy, and stem cell transplantation. Neurologic Complications of Cancer Therapy Features: A widely recognized team of editors Systemic therapy covered by therapeutic agent and by adverse event, enabling a "problem-oriented" approach for the clinician Coverage of newer modalities including immunologic agents, biologics, and targeted therapies Complete sections on complications of radiation therapy, surgery, high-dose chemotherapy, and stem-call transplantion
Neuro-Oncology—a new title in the Blue Books of Practical Neurology series—is a concise and clinically applicable guide to this dynamic subspecialty. Jeremy Rees, PhD, MRCP and Patrick Y. Wen, MD present the most current information on the treatment and management of primary CNS tumors, secondary brain tumors, and the neurological complications of other cancers and their therapies in a format and scope appealing to both the general neurologist and the subspecialist. Access comprehensive coverage of treatment for adult and pediatric conditions—including tumors of the spinal cord as well as the brain. Find coverage of recent advances easily thanks to the emphasis on the latest clinical and laboratory findings and their implications for clinical management and treatment. Apply the possibilities and outcomes of neuro-oncologic surgery within the context of neurologic practice. Address the neurologic complications of cancer and its treatment as well as of primary and secondary tumors. Tap into the global perspectives of experts from all around the world for a multi-disciplinary approach to practice.
Thank you for visiting our website. Would you like to provide feedback on how we could improve your experience?
This site does not use any third party cookies with one exception — it uses cookies from Google to deliver its services and to analyze traffic.Learn More.